The nigrostriatal dopaminergic pathway in Wilson’s disease studied with positron emission tomography

Barry J Snow, Mohit Bhatt, W R Wayne Martin, David Li, Donald B Calne

Abstract

Movement disorders, including Parkinsonism, are prominent features of neurological Wilson’s disease (WD). This suggests there may be dysfunction of the nigrostriatal dopaminergic pathway. To explore this possibility, five patients were studied using positron emission tomography (PET) with \( ^{18}F\)-6-fluorodopa (6FD), and magnetic resonance imaging (MRI). We calculated striatal 6FD uptake rate constants by a graphical method and compared the results with those of 18 normal subjects. It was found that four patients with symptoms all had abnormally low 6FD uptake, and the one asymptomatic patient had normal uptake. PET evidence for nigrostriatal dopaminergic dysfunction was present even after many years of penicillamine treatment. It is concluded that the nigrostriatal dopaminergic pathway is involved in neurological WD.

Wilson’s disease (WD) is an autosomal recessive disorder characterised by widespread copper deposition throughout the body, particularly in the liver and brain.1 Neurological presentation varies with combinations of psychiatric disturbance, involuntary movements, incoordination and dysarthria; pyramidal tract abnormalities are minimal, and sensation is spared. Pathological studies,23 computerised tomography (CT)45, and magnetic resonance imaging (MRI)46 show that the predominant lesions are in the basal ganglia, particularly the lentiform nucleus.

The prominence of movement disorders, including Parkinsonism, raises the question whether there is also a predilection for the nigrostriatal dopaminergic pathway to be involved in WD. There is only limited necropsy information suggesting that the pathway may be damaged in WD.510 Although the structural integrity of the striatum and substantia nigra may be studied with CT and MRI, these modalities cannot study the functional integrity of the dopaminergic system. Until now, there has been no satisfactory method of studying the function of the nigrostriatal dopaminergic pathway in living subjects.

With the advent of positron emission tomography (PET) using the tracer \( ^{18}F\)-6-fluorodopa (6FD), we can investigate the function of the nigrostriatal dopaminergic pathway in vivo.11 Following administration, radioactive metabolites of 6FD accumulate in the striatal endings of nigrostriatal dopaminergic neurons. PET can image this accumulation and thereby display the anatomical distribution of the intact nerve terminals.12 In addition, tracer-uptake data gathered during the scan, can be used to derive a 6FD uptake rate constant. This constant is an index of the activity of the enzyme dopa-decarboxylase that metabolises dopa to dopamine.11 Necropsy studies show that dopa-decarboxylase activity decreases with age and is diminished in Parkinson’s disease.514 PET studies agree with this necropsy data, showing decreases in 6FD accumulation with age and in Parkinson’s disease.1115-17 In addition, PET is sufficiently sensitive to demonstrate asymptomatic dopaminergic lesions in humans and monkeys.1819

WD has not previously been studied with 6FD PET. We employed this technique to determine if the nigrostriatal dopaminergic pathway is damaged in WD. We compared five patients with 18 controls.

Patients

The diagnosis of WD was based on the following established criteria in all patients: medical history, physical examination, Kayser-Fleischer rings confirmed on slit-lamp examination, low serum ceruloplasmin levels and elevated urinary copper excretion (table 1).20 The relevant clinical features of the patients are presented below. No patient had symptomatic liver disease or had other significant medical illness. Standard liver function tests were normal in all patients at the time of scanning (alkaline phosphatase, aspartate aminotransferase, gamma-glutamyl transferase and bilirubin). None had a history of exposure to phenothiazines or other dopamine receptor antagonists. When studied, no patient had ataxia, pyramidal tract signs, or sensory changes. The control group consisted of 18 subjects (mean age 40-2 years, range 22-54); all were neurologically normal and none were taking medication at the time of scanning.

Patient 1 was a 23 year old man who was diagnosed as having WD at age 12 when he developed predominantly Parkinsonian features with slurred speech, clumsy hand movements, micrographia, and a slowed gait. There was an intention tremor of the right hand. He was started on penicillamine 2 gm daily and improved steadily. When studied...
The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography

**Table 1** Biochemical findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>Ceruloplasmin (mg/100 ml)</th>
<th>Urinary Copper (ug/24 hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&lt;7</td>
<td>930</td>
</tr>
<tr>
<td>2</td>
<td>&lt;7</td>
<td>114*</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>145*</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>290*</td>
</tr>
<tr>
<td>5</td>
<td>&lt;7</td>
<td>210*</td>
</tr>
</tbody>
</table>

*Measurement taken while on treatment.

the only abnormal findings were mild dysarthria and impaired rapid alternating movements of the hands.

**Patient 2** was a 28 year old woman who presented at age 13 with tremor of the hands, drooling and slurred speech. Her twin brother had been diagnosed as having WD two years previously. She took penicillamine for two years then stopped for unknown reasons. At age 18 she was admitted to a psychiatric ward with disinhibited behaviour, drooling and dystonic hand movements; she improved on penicillamine. At age 26 she stopped her penicillamine again and within a month developed inappropriate laughter, unintelligible speech and dystonic hand movements. On penicillamine 2 gm per day she improved. When studied she had mild dementia and disinhibition, dysarthric but intelligible speech, and dystonic posturing of the upper limbs. There was no tremor, and no Parkinsonian features.

**Patient 3** was a 37 year old man who was diagnosed as having WD at age 30 when he sought an ophthalmological opinion regarding what were diagnosed as Kayser-Fleischer rings. Neurological examination revealed only a mild intention tremor of the right hand. On penicillamine 1 gm per day the rings and tremor resolved. When studied he was neurologically normal.

**Patient 4** was a 50 year old man who was diagnosed as having WD at age 18 when he developed slurring of speech, slow movements and drooling. An older brother had died of WD. Treatment with 2-3-dimercapto-pranol (BAL) resulted in a modest initial improvement, but he subsequently deteriorated. By age 30 he was bedbound with unintelligible speech, rigidity and weight loss. On penicillamine 2 gm per day he improved considerably. When studied he had predominantly Parkinsonian features with normal mentation, masked facies, dysarthric but intelligible speech, rigidity of all limbs, clumsy rapid alternating movements, an intention tremor and a shuffling unsteady gait.

**Patient 5** was a 51 year old woman who was diagnosed as having WD at age 27 when she presented with slurred speech, clumsy hands and tremor of the arms. On penicillamine 1 gm per day her symptoms stabilised. When studied she had predominantly Parkinsonian features with mild dementia, dysarthric but intelligible speech, a resting tremor of the right hand, rigidity, clumsy rapid alternating movements and an unstable gait.

**Methods**

The methods employed for PET have been described in detail elsewhere. The UBC/TRIUMF PETT VI system was operated in the high resolution mode. The system simultaneously collects data from seven contiguous axial slices with a centre to centre separation of 14.4 mm, in-plane resolution averaging 9.2 mm full width half maximum (FWHM), and an average axial resolution of 11 mm FWHM. A transmission scan, using a ring source containing $^{68}$Ge, was performed before the emission scans to permit a measured attenuation correction to be applied to the emission data.

The patient's medications were withheld from the night before scanning. All subjects received 100 mg of carbidopa one hour before the scan. 6FD (2.0-3.5 mCi) was prepared as described previously and administered intravenously at the start of scanning. During the scanning period 29 sequential blood samples were drawn from an indwelling radial artery catheter, and the total radioactivity in each was determined in a well counter. Twelve sequential emission scans were performed, each of 10 minutes duration.

A graphical method was employed to calculate the steady state 6FD uptake rate constant for the whole striatum. This method incorporates both the measured blood radioactivity and the corrected striatal radioactivity. To determine striatal radioactivity, elliptical regions of interest (ROI) were applied visually on all slices in which radioactivity in excess of background was evident. To ensure inclusion of the whole striatum, a 12 cm$^2$ ROI was used to cover the entire area of the striatum plus some of the surrounding brain. To correct for the activity from the surrounding brain and for striatal activity emanating from non-fluorodopamine metabolites of 6FD, a ROI was applied over each posterior temporoparietal cortex and the activity recorded from this ROI was subtracted from that of the striatal ROI.

Our method of total striatal sampling with a large ROI minimises the partial volume effect that may occur in the presence of striatal atrophy. Because of the partial volume effect, PET may underestimate the radioactivity concentration in small structures as the counts are distributed over a larger area than the original structure. However, despite the wide distribution, the counts are conserved so a relatively large ROI will measure total radioactivity in the structure of interest.

The graphical method requires correction for the decreasing availability of 6FD to the striatum as it is metabolised in the periphery. In particular, allowance must be made for the action of catechol-O-methyl transferase on 6FD to form 3-O-methyl-6FD (3-OMFD). We measured the plasma concentration of 3-OMFD by the method described by Boyes et al and calculated the ratio of 3-OMFD to 6FD in each blood sample. In previous studies, we expressed the increase of this ratio with time as the slope of a straight line calculated by regression analysis. However, inspection of the data
individual values were placed at 90% to test our hypothesis of a low 6FD uptake rate constant at a probability of 0.05 (one-sided). Patient 3 had a normal 6FD uptake rate constant; patients 1 and 4 had constants just below the confidence limit of the control group; the constants of patients 2 and 5 fell well below the confidence limit of the control group.

Analysis of covariance revealed a significant difference between the normal and WD groups (p = 0.001), with homogeneity of the slopes with age (p = 0.88).28

Selected PET and MRI images that best illustrate the abnormalities seen in each patient are shown in figs 2 and 3. The distribution of abnormal findings on MRI was similar to those reported in previous studies (table 2).6-8

Discussion
We have shown that the nigrostriatal dopaminergic pathway is variably damaged in WD. The variation in 6FD uptake rate constants between our patients is consistent with the clinical, radiological and MRI heterogeneity of the disease.29 Our results reinforce the concept that WD is a multifocal process.

Previous studies have suggested that a nigrostriatal dopaminergic lesion may be present in WD. Necropsy analyses in two patients found reduced striatal dopamine and tyrosine hydroxylase.9,10 Another study detected reduced cerebrospinal fluid dopamine metabolites in one patient with WD, while a sibling with asymptomatic disease had normal concentrations.20 Case reports have described a range of responses to levodopa in therapeutic trials.31-33 The variation may derive from different methods of study, or from different degrees of dopaminergic deficit. PET provides a more direct assessment of in vivo dopamine synthesis and storage than previous methods have allowed.

The PET images of our two patients with considerably reduced 6FD uptake suggest that the main loss of striatal radioactivity accumulation is in the region of the putamen with relative sparing of the caudate (patients 2 and 5, fig 2). This finding is consistent with necropsy observations suggesting preferential involvement of the putamen in WD.5

Despite the normal routine liver function tests, it is theoretically possible that hepatic dysfunction associated with WD may have increased plasma amino acid-levels which may in turn have competed with 6FD for transport across the blood-brain barrier. We investigated this by comparing the background activity (corrected for the dose of radioactivity injected) of the WD patients with the background activity of the control subjects. There was no significant difference [WD 0.22 (0.052), controls 0.21 (0.056), arbitrary units of radioactivity within the posterior temporo-parietal cortex ROIs]. Previous studies of 6FD PET with simultaneous amino-acid infusions in humans30 and monkeys (unpublished observations) have shown a decrease in background radioactivity. Thus we conclude that the decrease in striatal 6FD uptake seen in our

![Figure 1](image1.png)

Figure 1 6FD uptake constants plotted against age for five patients with Wilson's disease and 18 normal subjects. The regression line is for the normal subjects (r = 0.5 p < 0.05); the broken lines mark 90% confidence limits for prediction of individual values.

![Figure 2](image2.png)

Figure 2 6FD PET images in five patients with Wilson's disease and a normal subject (age 40 years) for comparison. Figures on the scale are radioactivity concentration in arbitrary units. The images represent 30 minutes of emission data acquired during the second hour after administration of the tracer.
The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography

Table 2  MRI Findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>Striata</th>
<th>Midbrain</th>
<th>Cerebral Hemispheres</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Increased signal from putamen</td>
<td>Atrophy</td>
<td>N</td>
</tr>
<tr>
<td>2</td>
<td>Caudate atrophy</td>
<td>Atrophy</td>
<td>Mild atrophy</td>
</tr>
<tr>
<td>3</td>
<td>Increased signal from caudate and putamen</td>
<td>Increased signal from the colliculi</td>
<td>Increased signal from periventricular white matter</td>
</tr>
<tr>
<td>4</td>
<td>N</td>
<td>Atrophy</td>
<td>Mild atrophy</td>
</tr>
<tr>
<td>5</td>
<td>N</td>
<td>Atrophy</td>
<td>Atrophy</td>
</tr>
</tbody>
</table>

No patient had focal MRI abnormalities in the region of the substantia nigra. N = no abnormality in the structure.
Figure 4 MRI image through the level of the midbrain of Patient 2 showing the midbrain atrophy and the increased signal from the colliculi (spin echo).

Figure 4 MRI image through the level of the midbrain of Patient 2 showing the midbrain atrophy and the increased signal from the colliculi (spin echo).

reinforces the importance of the early diagnosis and prompt treatment of WD.

We thank Sandra Cooper for her assistance with scanning as well as the members of the UBC/TRUMP PET team. Dr Michael Schulten assisted with statistical analysis. This study was supported by the Dysautonomic Medical Research Foundation, the American Parkinson’s Disease Association, and the New Zealand Neurological Foundation.

1 Cummings JN. The copper and iron content of brain and liver in the normal and in hepato-lobular degeneration. Brain 1948;71:410–1.
27 Boyes BE, Comming P, Martin WRW, McGee EJ. Determination of plasma [14F]-fluorodopa during...
The nigrostriatal dopaminergic pathway in Wilson’s disease studied with positron emission tomography


The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.
B J Snow, M Bhatt, W R Martin, D Li and D B Calne

J Neurol Neurosurg Psychiatry 1991 54: 12-17
doi: 10.1136/jnnp.54.1.12

Updated information and services can be found at:
http://jnnp.bmj.com/content/54/1/12

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/